Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.4631
- Book/Share 32.4389
- PB 5.1824
- Debt/Equity 0.1469
- CurrentRatio 1.0059
- ROIC 0.1216
- MktCap 404866037400.0
- FreeCF/Share 6.9307
- PFCF 24.148
- PE 17.946
- Debt/Assets 0.0596
- DivYield 0.0299
- ROE 0.3039
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
5 Dogs of the Dow Are Crushing the S&P 500 and Nasdaq in 2025
Published: July 28, 2025 by: 24/7 Wall Street
Sentiment: Neutral
The Dogs of the Dow is a well-known strategy first published in 1991 by Michael O'Higgins.
Read More
US FDA says J&J's Ethicon issues correction related to surgical stapler
Published: July 25, 2025 by: Reuters
Sentiment: Negative
The U.S. drug regulator said on Friday Ethicon Endo-Surgery, a unit of Johnson & Johnson , issued a correction for certain lots of a part related to its surgical stapler and classified the action as "most serious".
Read More
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's Innovative Medicine unit posts solid Q2 growth despite Stelara's LOE, powered by Darzalex, Tremfya, Erleada and new drugs.
Read More
Johnson & Johnson Stock Could Be Waking Up
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson's stock appears undervalued, as sluggish revenue growth and margin contraction are offset by raised full-year guidance and a rebounding outlook. Both Innovative Medicine and MedTech segments show promising pipeline developments, with MedTech's growth and robotics ambitions offering future upside. Despite a dip in free cash flow, J&J's dividend remains attractive, with a solid 3.18% yield and a 62-year growth streak, supporting shareholder returns.
Read More
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
Read More
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Read More
Best Dividend Kings: July 2025
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently appear undervalued with strong long-term return potential, using Dividend Yield Theory for valuation.
Read More
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
Insider report: These stocks had the biggest sales by executives in the past week
Published: July 21, 2025 by: CNBC
Sentiment: Negative
Some investors follow company insiders on the notion that they would know better than anyone when it's the right time to buy or sell shares. CNBC rounded up some of the biggest sales over the last week.
Read More
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
Read More
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech sales.
Read More
Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis
Published: July 21, 2025 by: PRNewsWire
Sentiment: Neutral
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies , including head-to-head superiority comparisons versus deucravacitinib and evaluation of difficult to treat skin sites Submission underscores potential to shift the treatment paradigm for moderate-to-severe plaque psoriasis patients with the standout combination of complete skin clearance, a favorable safety profile, and simplicity of a once daily pill SPRING HOUSE, Pa. , July 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the submission of a New Drug Application …
Read More
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
Read More
Want Steady Income? 3 Top Dividend Stocks for July 2025
Published: July 17, 2025 by: MarketBeat
Sentiment: Positive
Earnings season is synonymous with market volatility. Growth-oriented investors may love trading the ups and downs, but more risk-averse investors may look for ways to generate solid returns balanced by steady cash flow.
Read More
Johnson & Johnson: The Worst Is Baked In
Published: July 17, 2025 by: Seeking Alpha
Sentiment: Neutral
J&J's diversified business, robust pipeline, and strong free cash flow provide stability despite ongoing legal overhang from talcum powder claims. Legal risks remain a near-term headwind, but I believe any settlement will be manageable for J&J's financial strength and present a buying opportunity. J&J's 63-year dividend growth streak, solid payout ratio, and AAA credit rating make it an attractive choice for long-term, income-focused investors.
Read More
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.
Read More
Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer
Published: July 17, 2025 by: PRNewsWire
Sentiment: Neutral
New Drug Application supported by results from the Phase 2b SunRISe-1 study RARITAN, N.J. , July 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for TAR-200, an intravesical gemcitabine releasing system, for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.
Read More
S&P 500 Gains and Losses Today: Johnson & Johnson Stock Jumps; Universal Health Services Shares Slide
Published: July 16, 2025 by: Investopedia
Sentiment: Positive
Major U.S. equities indexes ticked higher Wednesday as President Donald Trump refuted reports that he is planning the immediate dismissal of Federal Reserve Chair Jerome Powell and questions about his legal ability to do so.
Read More
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
Published: July 16, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) Q2 2025 Earnings Conference Call July 16, 2025 8:30 AM ET Company Participants Darren Snellgrove - Corporate Participant Jennifer L. Taubert - Executive VP & Worldwide Chairman of Innovative Medicine Joaquin Duato - CEO & Chairman John C.
Read More
2 Dividend Giants Every Passive Income Investors Should Own
Published: July 16, 2025 by: 24/7 Wall Street
Sentiment: Positive
It's never been easier as a passive income investor to give your yield a bit of a jolt with the rise of covered call (and premium income) ETFs that trade off a bit of upside potential for some premiums.
Read More
Johnson & Johnson Stock Jumps on Strong Earnings, Higher Outlook
Published: July 16, 2025 by: Investopedia
Sentiment: Positive
Johnson & Johnson (JNJ) shares surged Wednesday after the company reported second-quarter results that topped estimates and the company lifted its full-year outlook.
Read More
Final Trades: Johnson & Johnson, ICE and the IBIT
Published: July 16, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their stop stocks to watch for the second half.
Read More
Top Stock Movers Now: J&J, ASML, Tesla, and More
Published: July 16, 2025 by: Investopedia
Sentiment: Negative
Major U.S. equities indexes were little changed at midday Wednesday after a report on wholesale inflation showed a surprising slowdown in June.
Read More
PPI Remained Unchanged
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Pre-market futures are climbing into the green this morning, following a cooler-than-expected wholesale inflation report and better-than-expected financial Q2 earnings numbers out before the bell today. After starting off roughly -0.1% across the board, we're currently up +160 points on the Dow, +13 points on the S&P 500 and +14 on the Nasdaq.
Read More
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.
Read More
J&J CFO: We're pleased with the engagement with the Trump administration
Published: July 16, 2025 by: CNBC Television
Sentiment: Positive
Johnson & Johnson CFO Joseph Wolk said Wednesday that the company is pleased with its engagement with the Trump administration, especially around tax policy, crediting the 2017 tax cuts for driving J&J's $55 billion U.S. investment and expanded biopharma manufacturing.
Read More
Johnson & Johnson (JNJ) Reports Q2 Earnings: What Key Metrics Have to Say
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Johnson & Johnson delivers earnings beat, raises full year sales and profit guidance
Published: July 16, 2025 by: Proactive Investors
Sentiment: Positive
Johnson & Johnson (NYSE:JNJ) shares edged higher premarket as the healthcare firm reported an earnings beat for the second quarter and raised its full-year guidance. For Q2, revenue of $23.74 billion was up 5.8% year-over-year and ahead of estimates of $22.83 billion, driven by strong sales of cancer treatments, notably Darzalex, and medical devices.
Read More
Top Beauty and Cosmetics Stocks That May Drive Long-Term Growth
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
EL, COTY and ULTA are tapping AI, e-commerce, and clean beauty to ride the next wave of long-term industry growth.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100